Articles On Somnomed (ASX:SOM)

Mesoblast expects FDA stem cell drug approval by the first week of January ‘if not earlier’ FDA to Somnomed: ‘do you want the good news or bad news first?’ Neurotech mulls its US options after FDA’s orphan drug decision Orthocell says reve...

Investors in ASX healthcare shares have had reason to smile this earnings season, with plenty of strong results so far. At the smaller end of town, two healthcare players have come in with solid results on Wednesday. These are Pacific S...

The Mesoblast Ltd (ASX: MSB) share price is under pressure on Tuesday. At the time of writing, the allogeneic cellular medicines developer's shares are down 4% to $1.04. Though, shareholders won't be too disheartened given that its shares r...

Mesoblast Ltd (ASX: MSB) shares are at it again today. And by 'it', I mean racing higher. Shares in the ASX biotech company closed yesterday trading for 79.5 cents. In afternoon trade on Tuesday, shares are swapping hands for 86 cents api...

It can be useful for investors to keep an eye on which shares have experienced meaningful insider buying. This is because insider buying is often regarded as a bullish indicator, as few people know a company and its intrinsic value better t...

The ASX200 closed the day down a third of a per cent, weighed down mostly by IT with Healthcare and Materials battling valiantly at the other end of the food chain. Healthcare led the gains, up more than a per cent, followed by materials...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another gain. At the time of writing, the benchmark index is up 0.5% to 7,863.6 points. Four ASX shares that have failed to follow the market higher today are...

The Australian Securities Exchange (ASX) is welcoming an AI exchange-traded fund (ETF) today. Artificial intelligence has captured the hearts and minds of investors with the popularisation of chatbots and AI-generated imagery. The promi...

ASX healthcare stock SomnoMed (ASX:SOM), a provider of sleep-related breathing solutions for the medical and dental markets, has declared a FY24 revenue downgrade while the stock remain in suspension. FY24 revenue growth has been downgra...

The ASX 200 erases early morning’s losses, rallying to close the day +0.3% higher.  This comes as the ABS released its monthly CPI report, which shows that YoY inflation was steady in February at 3.4% for a third straight month. The figure...

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.20% to 7,713.60. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spoti...

SomnoMed (ASX:SOM) appoints joint CEOs to accelerate growth SomnoMed aims to accelerate its revenue growth and profitability over the next 12 months as it plans to introduce its new Rest Assure® product Newly appointed Ms. Blickstead...

The local share market looks to rise half a per cent today off the back of records on Wall Street US overnight. This was largely due to the performance by semiconductor chip maker Nvidia, which shares have risen more than 16 per cent, re...

ASX 200 closes about 0.06% in the green (so, really, we ended in the chartreuse) down -1.2 in August Telco and IT Sectors offset Staples and Energy losses Small cap winners include 29M, CDX and HLA   Volatility, uncertainty and indecisio...

It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings lodgements.  Several small caps from Tech and Healthcare released their reports today, showing that they’re still thriving despite...

Today, Wednesday the 24th of August, we are happy to buy ALS Ltd (ASX:ALQ), Breville Group Ltd (ASX:BRG), HUB24 Ltd (ASX:HUB), Step One (ASX:STP) and SomnoMed Limited (ASX:SOM).

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. The health sector falls sligh...

It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The last day for companies to submit reports is the last business day of the first month after the prior quarter. If they don’t, they...

Highlights The benchmark ASX 200 index fell 0.99% or to 7,245.7 in early trade. US stocks plunged on Tuesday and European stocks continued extending their losses for a third consecutive day. EML Payments was the top loser, falling ove...

Today, Wednesday the 23rd of February, we are happy to buy Cochlear (ASX:COH), HUB24 (ASX:HUB), Coles Group (ASX:COL), Peter Warren (ASX:PWR), Superloop Limited (ASX:SLC), Step One Limited (ASX:STP), Costa Group (ASX:CGC), Jumbo Interactive...

Australian medical device company and global supplier of rapid diagnostic testing devices (RDT), Atomo (ASX: AT1) has scored distribution rights for rapid antigen tests in New Zealand, after being authorised by the New Zealand Ministry of H...

Alloggio Group (ASX:ALO), didn’t have a positive debut on the ASX last week but that didn’t stop one director from buying more on market. The holiday accommodation manager listed at 20 cents per share but fell as low as 15 cents on debut am...

Summary The S&P/ASX200 opened higher and gained 0.5% to hit an all-time high of 7,433.5.  The market rally was driven by solid gains across material, energy and A-REIT sectors. Iron ore miners BHP and Rio Tinto hit their respectiv...

World Overnight SPI Overnight (Jun) 7394.00 + 6.00 0.08% S&P ASX 200 7386.20 + 6.70 0.09% S&P500 4223.70 – 22.89 – 0.54% Nasdaq Comp 14039.68 – 33.17 – 0.24% DJIA 34033.67 – 265.66 – 0.77% S&P500 VIX 18.15 + 1.13 6...

The markets opened on a weak note on Tuesday morning. The benchmark ASX 200 was trading lower by 49 basis points at 7011.20. Of 11 sectors, 9 were trading lower today, with Materials being the best performing sector by lunchtime. Also read...

Today, Wednesday the 24th of February, we are happy to buy APA Group (ASX:APA), HUB24 (ASX:HUB), Superloop (ASX:SLC), Acrow Formwork (ASX:ACF), Jumbo Interactive (ASX:JIN), MyDeal.com.au (ASX:MYD), Ramelius Resources (ASX:RMS), Garda Proper...

The Somnomed Limited (ASX: SOM) share price closed 2.3% lower today at $2.12. While the SomnoMed share price has bounced back 67.5% over the past half year, it still remains more than 11% down on this time last year. We take a closer look...

The Rhinomed Ltd (ASX: RNO) share price surged to a six-month high as it takes a leaf out of the Starpharma Holdings Limited (ASX: SPL) playbook. The Rhinomed share price rallied 84% ahead of the market close to $0.14 after management said...

Michael Gable is an expert guest commentator for the Finance News Network, presenting “Stock Watch” each week – covering stock tips and shares on the Australian market (ASX). This video is dated 14 September 2020.  Shares covered: Nasdaq, (...

World Overnight SPI Overnight (Sep) 6076.00 – 9.00 – 0.15% S&P ASX 200 6126.20 + 9.80 0.16% S&P500 3484.55 + 5.82 0.17% Nasdaq Comp 11625.34 – 39.72 – 0.34% DJIA 28492.27 + 160.35 0.57% S&P500 VIX 24.47 + 1.20 5.16...

ShareCafeOvernight: Fly Me To The Moon World Overnight SPI Overnight (Sep) 6095.00 + 15.00 0.25% S&P ASX 200 6116.40 – 45.00 – 0.73% S&P500 3478.73 + 35.11 1.02% Nasdaq Comp 11665.06 + 198.59 1.73% DJIA 28331.92 + 83.48...

World Overnight SPI Overnight (Sep) 6095.00 + 15.00 0.25% S&P ASX 200 6116.40 – 45.00 – 0.73% S&P500 3478.73 + 35.11 1.02% Nasdaq Comp 11665.06 + 198.59 1.73% DJIA 28331.92 + 83.48 0.30% S&P500 VIX 23.27 + 1.24 5.6...

ShareCafeOvernight: Normal Service Resumed World Overnight SPI Overnight (Sep) 6132.00 + 39.00 0.64% S&P ASX 200 6161.40 + 31.80 0.52% S&P500 3443.62 + 12.34 0.36% Nasdaq Comp 11466.47 + 86.75 0.76% DJIA 28248.44 – 60.02...

World Overnight SPI Overnight (Sep) 6132.00 + 39.00 0.64% S&P ASX 200 6161.40 + 31.80 0.52% S&P500 3443.62 + 12.34 0.36% Nasdaq Comp 11466.47 + 86.75 0.76% DJIA 28248.44 – 60.02 – 0.21% S&P500 VIX 22.03 – 0.34 – 1....

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((CNU)) - Chorus ((ASB)) - Austal ((AVN)) - Aventus Group ((FMG)) - Fortescue ((GEM)) - G8 Education ((IFM)) - Infomedia ((ISD)) - Isentia ((KPG)) - Kelly Partners ((MVF))...

SomnoMed (ASX:SOM) is the latest Australian health company to look to Silicon Valley for its board, although it has pilfered from a division closer to home than the US. The company brought onto the board Amrita Blickstead, Ebay’s Australia...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Two out of...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Scott Powe...

COVID-19 has resulted in radical shifts in the health sector such as the adoption of tele-health, but the pandemic hasn’t been without financial impact. With the deadline for lodging 4C reports looming next Friday the first results trickled...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 134-odd small cap health stocks and of those which were trading on Wednesday, 71 were in positive territory over the last fortnight, 11 were flat and 52 saw...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week As markets...

Optimism is returning to the sleep apnoea market as Somnomed (ASX:SOM) says the nightmares that prompted a $15.5m capital raising in March haven’t returned. In fact, “trading has been better than expected and forecast” since the company rai...

2020 was looking good for many companies but COVID-19 changed all that. Some have needed capital to keep going and one was sleep apnoea mouthguard maker Somnomed (ASX:SOM). In February, the company reported solid revenue and operating profi...

Sleep apnoea treatment company SomnoMed (ASX: SOM) was caught napping in 2018 when an ambitious US direct-to-consumer model failed to deliver results, sending shares plunging and triggering a retreat and rethink. Known as Renew Sleep Solu...

Sleep apnoea — or sleep suffocation as some have taken to calling it — is big business on the ASX, spanning billion-dollar ResMed (ASX:RMD) to a group of small caps. Oventus (ASX:OVN), one of those small caps, is the latest this month to ad...

The venerable sleep disorders house is starting to sound like a car maker that has exhausted the possible names for its variant models and is now relying on letters, dashes, errant capital letters and numbers. A case in point is ResMed’s (A...

The SomnoMed Limited (ASX: SOM) share price has closed the trading day at a 52-week-high, after surging nearly 6% in today’s trading session and closing at $3.23.  The company’s share price has made a spectacular recovery in the last 12 mo...

Quarterly reports for biotechs usually only tell investors how much cash they have left — and how much time they have until the next cap raise. But December quarterlies from late Friday and today include several companies that are making mo...

Medical cannabis company Impression Healthcare (ASX: IHL) is continuing on its path to developing an effective solution for obstructive sleep apnoea (OSA) having filed a patent application covering IHL-42X in pill form. Impression intends t...

Australian-headquartered global pharmaceutical leader, SUDA Pharmaceuticals Limited (ASX: SUD) is engaged in the reformulation of existing drugs and provision of medication via the oral mucosa. The company uses its exclusive OroMist® techno...